Velodyne Lidar Powering Intelligent Traffic Management in Nevada
12.8.2020 15:00:00 EEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced a partnership with University of Nevada, Reno to advance research in transportation infrastructure. The university’s Nevada Center for Applied Research purchased and, in conjunction with the Nevada DOT and Nevada Governor’s Office of Economic Development, is using Velodyne’s lidar sensors in its Intelligent Mobility initiative to collect data aimed at making transportation more efficient, sustainable and safe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005076/en/
The University of Nevada, Reno’s Nevada Center for Applied Research has integrated Velodyne Ultra Puck lidar sensors with traffic signals to detect, count and track pedestrians, cyclists and traffic. (Photo: Velodyne Lidar, Inc.)
The program has integrated Velodyne Ultra Puck lidar sensors with traffic signals to detect, count and track pedestrians, cyclists and traffic to help improve traffic analytics, congestion management and pedestrian safety. These lidar sensors have been placed at crossing signs and intersections in the city of Reno, Nevada, and because lidar used today does not allow for facial recognition, these smart city applications can preserve trust and anonymity among the public.
“Lidar-enhanced” roads can also communicate data to connected vehicles to support eco-drive and collision avoidance applications. To address roadway congestion monitoring, university researchers have developed speed measurement, and delay and queue length measurements using lidar data.
The program also has an electric bus operated by the Regional Transportation Commission of Washoe County. The bus is equipped with an Ultra Puck and other sensors to collect data to assess mass-transit routes and feasibility of mass-transit automation in city segments with a connected infrastructure.
“Velodyne’s lidar sensors have been instrumental in our transportation research, providing the accurate, reliable 3D data we need in our Intelligent Mobility program,” said Carlos Cardillo, Director, Nevada Center for Applied Research. “Velodyne sensors are helping us address the challenge of improving mobility and safety in transportation, and contribute to advancing smart cities.”
“The Nevada Center for Applied Research is charting a path to create the smart cities of the future by enabling multimodal communication between infrastructure, vehicles and people,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Their multidisciplinary research team is using Velodyne’s lidar sensors in innovative ways to collect and analyze data needed to improve efficiency and safety.”
The Velodyne Ultra Puck provides a full 360-degree environmental view to deliver accurate real-time 3D data. It is a small, compact lidar sensor that delivers 200 meters range. The sensor’s reliability and power efficiency make it an ideal solution for smart city applications such as pedestrian safety, vehicle traffic and parking space management, and more. The Ultra Puck does not identify individuals’ facial characteristics, addressing a growing concern for civic applications.
To learn more about the University of Nevada, Reno’s Intelligent Mobility initiative and the coalition of public and private partners actively participating, please go to unr.edu/intelligent-mobility.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005076/en/
Contact information
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom